Patterns of Care: Understanding and Optimizing the Current Management of Metastatic Prostate Cancer in the Real World

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported with enzalutamide in the Phase III ENZAMET trial evaluating the addition of enzalutamide versus standard nonsteroidal antiandrogen drugs to testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC)?
   a. A significant improvement in progression-free survival alone
   b. A significant improvement in overall survival alone
   c. A significant improvement in both progression-free and overall survival

2. Which of the following observations was reported in the STAMPEDE trial evaluating the addition of abiraterone to androgen deprivation therapy (ADT) for patients with locally advanced or metastatic prostate cancer?
   a. A higher incidence of Grade ≥3 cardiovascular and hepatic disorders with abiraterone/ADT
   b. No difference in the incidence of any Grade ≥3 toxicities between the trial arms

3. Which of the following results was reported from the Phase II TheraP trial (ANZUP protocol 1603) presented at ASCO 2020 and comparing 177Lu-PSMA-617 to cabazitaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) who experienced disease progression after docetaxel therapy?
   a. Significantly higher rates of neutropenia, diarrhea and neuropathy with 177Lu-PSMA-617
   b. Higher rate of 50% decline in PSA with 177Lu-PSMA-617
   c. Higher rate of 50% decline in PSA with cabazitaxel

4. Results from the CHAARTED trial evaluating the addition of docetaxel to ADT for patients with mHSPC included which of the following outcomes?
   a. Statistically significant overall survival benefit with chemohormonal therapy for patients with high-volume disease only
   b. Statistically significant overall survival benefit with chemohormonal therapy for patients with high-volume or low-volume disease

5. Which overall survival outcome was reported with the addition of abiraterone/prednisone to ADT versus ADT alone for patients with newly diagnosed mHSPC in the LATITUDE trial?
   a. A significant improvement in overall survival with abiraterone
   b. No significant improvement in overall survival with abiraterone

6. Which of the following drug types best describes the mechanism of action of the novel agent ipatasertib?
   a. Antibody against PSMA
   b. AKT inhibitor
   c. Immune checkpoint inhibitor

7. Emerging data evaluating the combination of abiraterone and ipatasertib for patients with mCRPC have demonstrated which of the following outcomes?
   a. Progression-free survival benefit for patients with PTEN loss only
   b. Progression-free survival benefit for patients with PTEN loss and in the overall population

Patterns of Care: Understanding and Optimizing the Current Management of Metastatic Prostate Cancer in the Real World

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. **Results from the CARD trial evaluating cabazitaxel versus either of the targeted androgen-signaling inhibitors abiraterone or enzalutamide for patients with mCRPC previously treated with docetaxel who experienced disease progression within 12 months of receiving the alternative inhibitor demonstrated which of the following overall survival outcomes?**

   a. No difference between the treatment arms

   b. A significant improvement with cabazitaxel

   c. A significant improvement with either androgen-signaling inhibitor

9. **Which of the following side effects are more likely to be experienced by patients receiving treatment with apalutamide?**

   a. Diarrhea, alopecia, seizures

   b. Neutropenia, neuropathy, peripheral edema

   c. Rash, hypothyroidism, fractures

10. **Olaparib was recently approved by the FDA for patients with mCRPC who experience disease progression after prior treatment with enzalutamide or abiraterone and who harbor which gene mutations?**

    a. Any deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutation

    b. Germline BRCA1/2 mutations only